Ecopetrol SA(EC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

EC Ecopetrol SA

Closed 04-02 16:00:00 EDT

10.63

+0.02

+0.19%

盘后10.42

-0.21-1.98%

19:52 EDT

High10.66	Low10.41	Vol2.45M
Open10.58	D1 Closing10.61	Amplitude2.36%
Mkt Cap21.85B	Tradable Cap2.48B	Total Shares2.06B
T/O25.94M	T/O Rate1.05%	Tradable Shares233.42M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"EC","market":"US","secType":"STK","nameCN":"Ecopetrol SA","latestPrice":10.63,"timestamp":1743624000000,"preClose":10.61,"halted":0,"volume":2453220,"hourTrading":{"tag":"盘后","latestPrice":10.42,"preClose":10.63,"latestTime":"19:52 EDT","volume":42878,"amount":451893.1089,"timestamp":1743637945637},"delay":0,"floatShares":233421326,"shares":2055834734,"eps":1.647439,"marketStatus":"Closed","change":0.02,"latestTime":"04-02 16:00:00 EDT","open":10.58,"high":10.66,"low":10.41,"amount":25940289.40272,"amplitude":0.023563,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":1.647439,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1743667200000},"marketStatusCode":5,"adr":1,"adrRate":20,"listingDate":1221710400000,"exchange":"NYSE","adjPreClose":10.61,"preHourTrading":{"tag":"盘前","latestPrice":10.59,"preClose":10.61,"latestTime":"09:18 EDT","volume":2862,"amount":30384.214074,"timestamp":1743599910432},"postHourTrading":{"tag":"盘后","latestPrice":10.42,"preClose":10.63,"latestTime":"19:52 EDT","volume":42878,"amount":451893.1089,"timestamp":1743637945637},"volumeRatio":1.014299,"impliedVol":0.3001,"impliedVolPercentile":0.255},"requestUrl":"/m/hq/s/EC/tweets","defaultTab":"tweets","newsList":[{"id":"2524423451","title":"Ecopetrol (EC) Rises But Trails Market: What Investors Should Know","url":"https://stock-news.laohu8.com/highlight/detail?id=2524423451","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524423451?lang=en_us&edition=full_marsco","pubTime":"2025-04-03 05:50","pubTimestamp":1743630615,"startTime":"0","endTime":"0","summary":"Ecopetrol  closed the most recent trading day at $10.63, moving +0.19% from the previous trading session. The stock's performance was behind the S&P 500's daily gain of 0.67%. Elsewhere, the Dow gained 0.56%, while the tech-heavy Nasdaq added 0.87%.Shares of the oil and natural gas exploration company have appreciated by 16.47% over the course of the past month, outperforming the Oils-Energy sector's gain of 3.06% and the S&P 500's loss of 5.28%.The investment community will be closely monitoring the performance of Ecopetrol in its forthcoming earnings report. The company is predicted to post an EPS of $0.58, indicating a 16% growth compared to the equivalent quarter last year. Simultaneously, our latest consensus estimate expects the revenue to be $7.35 billion, showing a 7.89% drop compared to the year-ago quarter.It's also important for investors to be aware of any recent modifications to analyst estimates for Ecopetrol. These recent revisions tend to reflect the evolving nature of ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ecopetrol-ec-rises-trails-market-215015228.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ISBC","BK4211","BK4201","EC"],"gpt_icon":0},{"id":"2524437438","title":"Market Chatter: Ecopetrol Mulls Buying SierraCol Energy From Carlyle Group","url":"https://stock-news.laohu8.com/highlight/detail?id=2524437438","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524437438?lang=en_us&edition=full_marsco","pubTime":"2025-04-02 16:24","pubTimestamp":1743582257,"startTime":"0","endTime":"0","summary":"Ecopetrol  is considering acquiring Carlyle Group's  Colombian oil driller, SierraCol Energy, to boost reserves and output, Bloomberg reported late Tuesday, citing an interview with Ecopetrol executives.Reuters reported last month that Carlyle is looking to sell SierraCol for $1.5 billion, Bloomberg said.\"We were invited to the process and are currently analyzing the option,\" Rafael Guzman, Ecopetrol's vice president of hydrocarbons, told Bloomberg. \"We have yet to decide if we present an offer.Carlyle Group didn't immediately respond to MT Newswires' request for comment.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE00B64PRP62.GBP","CG","EC","BK4201","BK4135","IE00B3QW5Z07.USD","IE00BGHQF748.EUR"],"gpt_icon":0},{"id":"2524913194","title":"Pharvaris says EC grants orphan designation to deucrictibant","url":"https://stock-news.laohu8.com/highlight/detail?id=2524913194","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524913194?lang=en_us&edition=full_marsco","pubTime":"2025-04-01 18:55","pubTimestamp":1743504949,"startTime":"0","endTime":"0","summary":"Pharvaris (PHVS) announced that the European Commission has granted orphan designation to its investigational drug, deucrictibant, for the treatmen...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/pharvaris-says-ec-grants-orphan-designation-to-deucrictibant?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/pharvaris-says-ec-grants-orphan-designation-to-deucrictibant?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4201","BK4007","PHVS","EC"],"gpt_icon":0},{"id":"2524191187","title":"Pharvaris Announces Orphan Designation Granted to Deucrictibant by the European Commission","url":"https://stock-news.laohu8.com/highlight/detail?id=2524191187","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524191187?lang=en_us&edition=full_marsco","pubTime":"2025-04-01 18:50","pubTimestamp":1743504600,"startTime":"0","endTime":"0","summary":"ZUG, Switzerland, April  01, 2025  (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/04/01/3053128/0/en/Pharvaris-Announces-Orphan-Designation-Granted-to-Deucrictibant-by-the-European-Commission.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4198","IE00BLDYK493.USD","EC","HAE","LU0012050646.USD","LU1169589451.USD","BK4201","IE00B64QTZ34.USD","LU1169590202.USD","LU0205193047.USD","LU0205194284.USD","LU0106261612.USD"],"gpt_icon":0},{"id":"2524219948","title":"The European Commission refers lecanemab decision to Appeal Committee","url":"https://stock-news.laohu8.com/highlight/detail?id=2524219948","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524219948?lang=en_us&edition=full_marsco","pubTime":"2025-04-01 18:17","pubTimestamp":1743502620,"startTime":"0","endTime":"0","summary":"STOCKHOLM, April 1, 2025 /PRNewswire/ --BioArctic AB's   partner Eisai today announced that the European Commission  has decided to refer the marketing authorisation approval decision of lecanemab in the EU to the Appeal Committee.If the marketing authorization application for lecanemab is approved, the approval will apply to all 27 European Union member states, as well as Iceland, Liechtenstein, and Norway. Leqembi is already approved in the US, Japan, China, Great Britain and other markets.Lecanemab is approved in the U.S., Japan, China, United Kingdom, and several other markets for the treatment of mild cognitive impairment  due to Alzheimer's disease  and mild AD dementia. Lecanemab's approvals in these countries, as well as the CHMP's positive opinion in November 2024, were primarily based on Phase 3 data from Eisai's global Clarity AD clinical trial, in which it met its primary endpoint and all key secondary endpoints with statistically significant results. Eisai has also submitt","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/european-commission-refers-lecanemab-decision-101700021.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/european-commission-refers-lecanemab-decision-101700021.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BK4585","BK4588","BRCTF","EC","BK4215","MAA","MCI","CHMP","BK4087","BK4201"],"gpt_icon":0},{"id":"2524016956","title":"European Commission Approves Pfizer’s RSV Vaccine ABRYSVO® to Help Protect Adults Aged 18-59 Against RSV Lower Respiratory Tract Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2524016956","media":"Business Wire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524016956?lang=en_us&edition=full_marsco","pubTime":"2025-04-01 15:00","pubTimestamp":1743490800,"startTime":"0","endTime":"0","summary":"ABRYSVO is the first and only RSV vaccine approved in the European Union  for non-pregnant adults aged 18-49. NEW YORK, April 01, 2025----Pfizer Inc.  announced today that the European Commission  has issued a decision amending the marketing authorization for ABRYSVO, the company’s bivalent respiratory syncytial virus  prefusion F  vaccine, to extend the indication to include prevention of lower respiratory tract disease  caused by RSV in individuals 18 through 59 years of age. This expands the previous authorization for individuals aged 60 and older, and ABRYSVO now offers in the EU the broadest RSV vaccine indication, which includes:. Active immunization of individuals 18 years of age and older for the prevention of LRTD caused by RSV. ABOUT RSVRespiratory Syncytial Virus  is a contagious virus and a common cause of respiratory illness worldwide.5 The virus can affect the lungs and breathing passages of an infected individual, potentially causing severe illness or death.6,7,8 There a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/european-commission-approves-pfizer-rsv-070000511.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0321505868.SGD","LU1894683264.USD","BK4087","IE00B19Z3581.USD","LU0456855351.SGD","IE0002270589.USD","LU0225771236.USD","EC","LU0321505439.SGD","LU0058720904.USD","BK4099","IE000M9KFDE8.USD","IE00BLSP4239.USD","LU0122379950.USD","BK4516","BK4585","LU0985481810.HKD","PFE","SG9999002224.SGD","SG9999002232.USD","LU0306807586.USD","BK4588","BK4201","BK4007","BK4581","LU1066053197.SGD","LU1894683348.USD","SG9999013999.USD","SGXZ57979304.SGD","CHMP","BK4599","F","BK4550","SG9999003800.SGD","BK4592","BK4568","BK4555","SG9999001176.SGD","LU1057294990.SGD","LU0289739699.SGD","BK4574","BK4156","BK4533","LU0234572021.USD","LU0868494617.USD","SG9999011175.SGD","LU1883839398.USD","LU0170899867.USD","BK4534"],"gpt_icon":1},{"id":"2524626974","title":"Press Release: ESS Tech, Inc. Announces Fourth Quarter and Full Year 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2524626974","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524626974?lang=en_us&edition=full_marsco","pubTime":"2025-04-01 04:05","pubTimestamp":1743451500,"startTime":"0","endTime":"0","summary":"Completed Commissioning and Grid Interconnection of First Two Energy Centers. Delivered Eight Energy Center Systems to Florida Utility. Achieved Breakeven Profitability on Energy Center Design at the end of Q4, Almost a Year Ahead of Schedule. Announced Energy Base, a New Modular, Non-Containerized Gigawatt-Hour scale LDES Solution. ESS Global Fleet Surpasses 2 GWh of Transacted Energy. ESS Tech, Inc.  , a leading manufacturer of iron flow long-duration energy storage  systems for commercial and utility-scale applications, today announced financial results for its fourth quarter and full year ended December 31, 2024.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["5AL.SI","EC","BK4588","BK4215","GWH","BK4585","BK4555","TM","BK4201","BK6088","03160","BK4604","ESS","BK4099","BK4597","BK4096","BK6522"],"gpt_icon":0},{"id":"2524718809","title":"Singapore’s private home price index eases to 0.6% in Q1: URA flash data","url":"https://stock-news.laohu8.com/highlight/detail?id=2524718809","media":"businesstimes","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524718809?lang=en_us&edition=full_marsco","pubTime":"2025-04-01 01:05","pubTimestamp":1743440706,"startTime":"0","endTime":"0","summary":"This follows a 2.3 per cent increase in Q4 last year, and a full-year price growth of 3.9 per cent in 2024","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"bustime_highlight","url":"https://www.businesstimes.com.sg/property/singapores-private-home-price-index-eases-0-6-q1-ura-flash-data","rn_cache_url":null,"customStyle":"","selectors":"body","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.businesstimes.com.sg/property/singapores-private-home-price-index-eases-0-6-q1-ura-flash-data","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"bustime_highlight","symbols":["BK4606","BK4588","URA","EC","BK4585","BK4201","CFA.SI"],"gpt_icon":0},{"id":"2523092138","title":"TIVDAK® (tisotumab vedotin) Approved by European Commission for Previously Treated Recurrent or Metastatic Cervical Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2523092138","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523092138?lang=en_us&edition=full_marsco","pubTime":"2025-03-31 23:20","pubTimestamp":1743434400,"startTime":"0","endTime":"0","summary":"Media Release COPENHAGEN, Denmark; March 31, 2025 TIVDAK is the first and only antibody-drug conjugate (ADC) approved to treat recurrent or metastatic cervical cancer with disease progression on or af","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/31/3052498/0/en/TIVDAK-tisotumab-vedotin-Approved-by-European-Commission-for-Previously-Treated-Recurrent-or-Metastatic-Cervical-Cancer.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU0225284248.USD","LU0321505439.SGD","BK4097","LU1057294990.SGD","BK4581","LU0985481810.HKD","LU1894683264.USD","PFS","SG9999002224.SGD","SGXZ57979304.SGD","BK4533","LU0868494617.USD","BK4534","LU0122379950.USD","LU0234572021.USD","L","LU1883839398.USD","BK4107","BK4080","BK4231","SG9999011175.SGD","ADC","IE00BBT3K403.USD","BK4599","IE000M9KFDE8.USD","OS","SG9999013999.USD","IE00B19Z3B42.SGD","EC","BK4201","LU0321505868.SGD","IE00B19Z3581.USD","LU1066051498.USD","MAA","SG9999003800.SGD","BK4592","IE0002270589.USD","ORR","BK4007","SG9999001176.USD","LU0053666078.USD","LU0306806265.USD","IE00BLSP4452.SGD","LU0289739699.SGD","LU0058720904.USD","LU0170899867.USD","BK4550"],"gpt_icon":1},{"id":"2523946601","title":"Primary Endpoint Met in Corcept’s Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2523946601","media":"Business Wire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523946601?lang=en_us&edition=full_marsco","pubTime":"2025-03-31 20:00","pubTimestamp":1743422400,"startTime":"0","endTime":"0","summary":"Relacorilant plus nab-paclitaxel improved progression-free and overall survival and did not increase side effect burden. Results will support a New Drug Application  in the United States and a Marketing Authorization Application  in Europe. Relacorilant plus nab-paclitaxel has the potential to become a new standard of care for patients with platinum-resistant ovarian cancer. REDWOOD CITY, Calif., March 31, 2025----Corcept Therapeutics Incorporated , a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that ROSELLA, the company’s pivotal Phase 3 trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer, met its primary endpoint of improved progression-free survival, as assessed by blinded independent central review .\"Patients with advanced ovarian cancer have few good treatment op","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/primary-endpoint-met-corcept-pivotal-120000306.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1559883803.SGD","LU0566484027.USD","BK4201","OS","MAA","BK4007","BK4588","BK4097","EC","BK4585","BK4532","BK4215","CORT"],"gpt_icon":0},{"id":"2522257316","title":"Bristol Myers Squibb Receives Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo® (nivolumab) Across Multiple Solid Tumor Indications","url":"https://stock-news.laohu8.com/highlight/detail?id=2522257316","media":"Business Wire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522257316?lang=en_us&edition=full_marsco","pubTime":"2025-03-28 20:00","pubTimestamp":1743163200,"startTime":"0","endTime":"0","summary":"Recommendation is based primarily on results from the Phase 3 CheckMate -67T trial which demonstrated noninferiority in the co-primary endpoints of Cavgd28 and Cminss and consistent efficacy in the secondary endpoint of overall response rate for the subcutaneous formulation of Opdivo vs. its intravenous formulation. A decision on the EU Opdivo extension of marketing authorization is expected by June 2, 2025. \"The positive CHMP opinion is an important step forward in the evolution of immuno-oncology and in the potential of subcutaneous nivolumab to help transform the lives of people living with cancer,\" said Dana Walker, M.D., M.S.C.E., Opdivo global program lead, Bristol Myers Squibb. \"We look forward to bringing the same high-quality care that transformed cancer treatment with an administration method that has the potential to improve the patient experience and efficiency of healthcare systems in Europe.\"","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bristol-myers-squibb-receives-positive-120000105.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4528","EC","BK4007","BK4532","ALK","IE0002141913.USD","TEN","LU2242652126.USD","LU0306807586.USD","LU1074936037.SGD","LU1670710661.SGD","LU0321505439.SGD","LU1670710588.SGD","LU1093756168.USD","LU0882574055.USD","BMY","UK","LU1032466523.USD","LU1261432733.SGD","BK4559","BK4534","RCC","BK4156","LU0868494617.USD","IE00BFTCPJ56.SGD","ORR","CHMP","LU0096364046.USD","CRT","MYE","VOD","BK4008","IE0009355771.USD","LU2133065610.SGD","LU1868836914.USD","EEA","BK4500","LU1291159041.SGD","LU1323610961.USD","LU1093756325.SGD","LU1670711123.USD","BK4585","LU0456855351.SGD","LU1670711040.USD","IE00BJJMRZ35.SGD","LU1718418525.SGD","HSCT","LU0237698245.USD","LU0061475181.USD"],"gpt_icon":0},{"id":"2522301593","title":"Market Chatter: EU Readies 'Robust' Response to New US Import Tariffs, EC Spokesman Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2522301593","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522301593?lang=en_us&edition=full_marsco","pubTime":"2025-03-27 21:48","pubTimestamp":1743083338,"startTime":"0","endTime":"0","summary":"The European Union is readying its response to US President Donald Trump's newly announced tariffs on imported vehicles, Reuters reported Thursday, citing European Commission spokesperson Olof Gill.Gill said the European Union's response to the tariffs will be \"timely,\" as well as \"robust\" and \"well calibrated,\" according to Reuters.The spokesperson didn't immediately respond to a request for comment from MT Newswires.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4156","BK4201","EC"],"gpt_icon":0},{"id":"2522533475","title":"Merck (NYSE:MRK) Gains EC Approval For CAPVAXIVE® Amid Recent 7% Share Price Dip","url":"https://stock-news.laohu8.com/highlight/detail?id=2522533475","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522533475?lang=en_us&edition=full_marsco","pubTime":"2025-03-27 01:32","pubTimestamp":1743010330,"startTime":"0","endTime":"0","summary":"Merck has recently achieved a significant milestone with the European Commission's approval of its pneumococcal vaccine CAPVAXIVE, boosting its portfolio in the vaccines market. Despite this positive development, the company's share price encountered a 1.82% decline over the last month, a period marked by substantial turmoil across global markets. Influenced by concerns related to potential U.S. tariffs and the broader selloff in the technology sector, many investors were cautious. While the market has seen a modest recovery, Merck's performance seemed to contrast with broader market trends, like the tech sector selloff impacting investor sentiment.View our complete analysis and fair value estimate and you decide.NYSE:MRK Revenue & Expenses Breakdown as at Mar 2025. Despite these successes, Merck's performance over the past year saw challenges. The decision to pause GARDASIL shipments to China due to inventory issues marked short-term disruptions. Similarly, regulatory hurdles and stif","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/merck-nyse-mrk-gains-ec-173210476.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1035773651.USD","SG9999014542.SGD","LU2023250843.SGD","LU2112291526.USD","LU1983299246.USD","LU1941712264.USD","LU0265550359.USD","LU1093756325.SGD","LU2023250504.SGD","LU2361045086.USD","MRK","IE00BSNM7G36.USD","IE0009355771.USD","LU0965509283.SGD","LU0208291251.USD","EC","LU2361044865.SGD","LU0238689110.USD","LU1571399168.USD","SG9999001176.SGD","BK4585","LU0320765489.SGD","LU1917777945.USD","LU1989772923.USD","LU0203347892.USD","LU2361044949.HKD","BK4550","LU2106854487.HKD","IE00B4R5TH58.HKD","NYSE","BK4559","BK4534","SG9999014559.SGD","SG9999013999.USD","SG9999015358.SGD","LU1699723380.USD","LU1941712348.USD","LU1974910355.USD","LU1023059063.AUD","BK4007","IE00BLSP4452.SGD","LU2089984988.USD","LU0289739699.SGD","LU1116320901.HKD","IE000M9KFDE8.USD","SG9999001176.USD","LU1066051811.HKD","LU0106261372.USD","LU1934455863.HKD","LU1989772840.SGD"],"gpt_icon":0},{"id":"2522808218","title":"How to link your Aadhaar Card to your Voter ID: A step-by-step guide","url":"https://stock-news.laohu8.com/highlight/detail?id=2522808218","media":"ByHT News Desk","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522808218?lang=en_us&edition=full_marsco","pubTime":"2025-03-26 18:59","pubTimestamp":1742986740,"startTime":"0","endTime":"0","summary":"This matter was discussed at a high-level meeting last week between senior officers of the Election Commission  and representatives from the Home Ministry, Law Ministry, IT Ministry, and UIDAI, and is likely to be part of the amended Form 6B, according to an Indian Express report. As a result, the following is all about how to link your Aadhaar to your Voter ID. Also Read: India to scrap ‘Google Tax’ from April 1: What is it?","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.hindustantimes.com/india-news/how-to-link-your-aadhaar-card-to-your-voter-id-a-step-by-step-guide-101742980576052.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"hindustan_highlight","symbols":["BK4201","EC"],"gpt_icon":0},{"id":"2522282027","title":"European Commission (EC) Approves Merck’s CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) for Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in Adults","url":"https://stock-news.laohu8.com/highlight/detail?id=2522282027","media":"Business Wire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522282027?lang=en_us&edition=full_marsco","pubTime":"2025-03-26 18:45","pubTimestamp":1742985900,"startTime":"0","endTime":"0","summary":"EC decision marks the fourth approval for CAPVAXIVE for pneumococcal vaccination in adults. This decision authorizes the marketing of CAPVAXIVE in all 27 European Union  member states, as well as Iceland, Liechtenstein and Norway. The timing for availability of CAPVAXIVE in individual countries will depend on multiple factors, including the completion of reimbursement procedures. CAPVAXIVE was approved in the U.S. in June 2024, in Canada in July 2024, and in Australia in January 2025.\"Pneumococcal disease continues to pose a significant risk for adults in Europe, among adults who are 65 or older, and also among younger adults who are immunocompromised or have chronic medical conditions,\" said Dr. Lina Pérez Breva, Vaccine Research, Fisabio - Public Health, Valencia, Spain. \"Based on data from the Phase 3 STRIDE clinical program, CAPVAXIVE offers coverage against the serotypes responsible for the majority of invasive disease cases in adults, making this approval in the EU an important s","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/european-commission-ec-approves-merck-104500234.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4156","LU1035773651.USD","LU1934455194.USD","LU0106261372.USD","SG9999015358.SGD","IE000M9KFDE8.USD","LU1989771016.USD","SG9999001176.USD","LU0006306889.USD","EC","SG9999015341.SGD","IE00BSNM7G36.USD","LU1116320737.USD","LU1069347547.HKD","MRK","LU1974910355.USD","IE0009355771.USD","BK4007","IE00BLSP4452.SGD","LU0265550359.USD","LU1941712348.USD","IE0002141913.USD","SG9999014575.USD","LU0058720904.USD","LU1057294990.SGD","LU1989772923.USD","LU1116320901.HKD","LU1093756325.SGD","SG9999001440.SGD","LU0965509101.SGD","IE00BJJMRZ35.SGD","LU2112291526.USD","LU1037948541.HKD","IE00BJT1NW94.SGD","LU1989772840.SGD","BK4534","IE00BBT3K403.USD","LU2324357040.USD","LU1291159041.SGD","LU0234572021.USD","LU1061106388.HKD","LU0265550946.USD","SG9999001176.SGD","LU1585245621.USD","BK4533","BK4201","IE00BLSP4239.USD","SG9999013999.USD","LU0211331839.USD"],"gpt_icon":0},{"id":"2522888186","title":"ECP Asset Management and EC Pohl & Co Cease Substantial Holding in Nanosonics Limited","url":"https://stock-news.laohu8.com/highlight/detail?id=2522888186","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522888186?lang=en_us&edition=full_marsco","pubTime":"2025-03-26 02:38","pubTimestamp":1742927881,"startTime":"0","endTime":"0","summary":"Nanosonics Limited ( ($AU:NAN) ) has shared an announcement. Nanosonics Limited announced that ECP Asset Management Pty Ltd and EC Pohl & Co Pty Lt...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/ecp-asset-management-and-ec-pohl-co-cease-substantial-holding-in-nanosonics-limited?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/ecp-asset-management-and-ec-pohl-co-cease-substantial-holding-in-nanosonics-limited?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EC","BK4201"],"gpt_icon":0},{"id":"2521724213","title":"Shell Invests in Gato do Mato to Drive Brazil's Pre-Salt Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2521724213","media":"Zacks","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521724213?lang=en_us&edition=full_marsco","pubTime":"2025-03-24 18:26","pubTimestamp":1742811960,"startTime":"0","endTime":"0","summary":"Shell plc’s SHEL subsidiary, Shell Brasil Petróleo Ltda. , has taken an important step in the development of Brazil's energy resources by approving the Final Investment Decision  for the Gato do Mato project. This deep-water venture, located in the pre-salt layer of the Santos Basin off the coast of Brazil, represents a breakthrough for both SHEL and the global energy market. The project is poised to significantly contribute to Brazil’s oil and gas industry, strengthening SHEL’s position as the largest foreign producer in the country.As a deep-water gas-condensate discovery, Gato do Mato promises to be a cornerstone for Brazil’s growing oil production. The project is designed to produce up to 120,000 barrels of oil per day, further contributing to the stability and expansion of Brazil's oil and gas sector.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/shell-invests-gato-mato-drive-102600796.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2129689431.USD","BK4585","LU0320765646.SGD","LU2236285917.USD","BK4179","LU2129689605.HKD","SHEL","BK4561","LU2237443382.USD","LU0278409577.USD","LU2237443895.HKD","LU2129689514.USD","LU1162221912.USD","LU2237443465.HKD","TTE","AROC","BK4201","BK4588","LU2237443978.SGD","LU0300736062.USD","LU2237443622.USD","LU0098860793.USD","LU2237443549.SGD","LU0300736492.USD","EC"],"gpt_icon":0},{"id":"2521244858","title":"Is Bristol-Myers Squibb (BMY) Among the Cheap Stocks to Buy According to Billionaires?","url":"https://stock-news.laohu8.com/highlight/detail?id=2521244858","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521244858?lang=en_us&edition=full_marsco","pubTime":"2025-03-23 04:04","pubTimestamp":1742673883,"startTime":"0","endTime":"0","summary":"We recently published a list of the 15 Best and Cheap Stocks to Buy According to Billionaires. In this article, we are going to take a look at where Bristol-Myers Squibb Company  stands against the other cheap stocks held by billionaires.The S&P 500 index is trading around its all-time high, and the short-term market indicators aren’t much evident with the latest U.S. tariff policy under implementation.Billionaire investor and CEO of Berkshire Hathaway Warren Buffett sold a record $134 billion worth of stock in 2024. Buffett’s move is considered a benchmark among investors to assess the market. Historically, when Buffett’s firm becomes a net seller, it’s often followed by below-average market performance. Many believe that this could be a signal of stock market underperformance in 2025. Cheap stocks held by billionaire investors can be a great option considering the current uncertainty in the market.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bristol-myers-squibb-bmy-among-200443552.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4533","LU0061475181.USD","BMY","LU1868837136.USD","LU0321505868.SGD","LU1363072403.SGD","LU0980610538.SGD","IE00BK4W5L77.USD","LU2133065610.SGD","LU1093756168.USD","LU0985481810.HKD","LU0096364046.USD","BK4532","IE00BK4W5M84.HKD","IE0002141913.USD","IE00BJJMRZ35.SGD","LU2125154935.USD","IE00BFXG1179.USD","LU0456855351.SGD","BK4550","LU0234570918.USD","LU1430594728.SGD","LU0251131958.USD","IE00BSNM7G36.USD","LU0787776722.HKD","LU1868836591.USD","LU1718418525.SGD","LU0742534661.SGD","LU1074936037.SGD","LU0130102774.USD","BK4176","LU1670711040.USD","LU0170899867.USD","LU1291159041.SGD","LU1571399168.USD","LU0971096721.USD","LU1868837300.USD","LU1670711123.USD","EC","IE00B3S45H60.SGD","LU0648001328.SGD","LU2360032135.SGD","LU1261432733.SGD","LU0306807586.USD","LU1868836757.USD","IE00B2B36J28.USD","BK4585","BK4201","LU0237698245.USD"],"gpt_icon":1},{"id":"2521815802","title":"Shell's Brazil Subsidiary Joins Consortium Developing Gato do Mato Offshore Project","url":"https://stock-news.laohu8.com/highlight/detail?id=2521815802","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521815802?lang=en_us&edition=full_marsco","pubTime":"2025-03-21 21:09","pubTimestamp":1742562591,"startTime":"0","endTime":"0","summary":"Shell  said Friday its Brasil subsidiary, Shell Brazil Petroleo, has joined a consortium holding stakes in the Gato do Mato deep-water project in the pre-salt area of the Santos Basin offshore of Brazil's Rio de Janeiro coast.Financial details of the investment in joining the consortium weren't disclosed.The Gato do Mato consortium now includes Shell, as operator of the project, with a 50% stake; Ecopetrol , with a 30% stake; TotalEnergies , with a 20% stake and the Brazil government's public company under its Ministry of Mines and Energy, Pre-Sal Petroleo, acting as the manager of the contract, Shell said.The project's recoverable resource volumes are estimated at about 370 million barrels. The project includes installation of a floating production storage and offloading vessel, and is designed to produce up to 120,000 barrels of oil per day once it is anticipated to begin operations in 2029, Shell said.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2237443549.SGD","LU2237443465.HKD","LU0278409577.USD","LU0320765646.SGD","BK4588","BK4201","LU0098860793.USD","BK4585","BK4561","LU0300736062.USD","LU2129689431.USD","TTE","LU0300736492.USD","LU2237443895.HKD","LU2129689514.USD","SHEL","LU2129689605.HKD","EC","LU2236285917.USD","LU2237443978.SGD","LU2237443622.USD","LU1162221912.USD","LU2237443382.USD"],"gpt_icon":1},{"id":"2520458334","title":"Press Release: InflaRx Reports Full Year 2024 Results and Highlights Key Achievements and Expected Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2520458334","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520458334?lang=en_us&edition=full_marsco","pubTime":"2025-03-20 19:30","pubTimestamp":1742470200,"startTime":"0","endTime":"0","summary":"-- Received European Commission approval for GOHIBIC  for. the treatment of SARS-CoV-2-induced acute respiratory distress syndrome. pyoderma gangrenosum  to enable an expected interim analysis for. trial size adaptation or futility by the end of May 2025. -- Dosed first patient in Phase 2a trial for oral C5aR inhibitor, INF904,INF904 in CSU and HS -- Topline Phase 2a data expected in summer 2025. In December 2024, InflaRx announced that the first patient had been dosed in its Phase 2a basket study with INF904 in CSU and HS. This is a multi-center, open-label study evaluating multiple INF904 dosing regimens over 4 weeks of treatment in a total of 75 patients . The goal of the trial is to generate additional safety and pharmacokinetic  data and to provide signs of clinical benefit. After the 4-week treatment period, patients will be follow","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU0689626769.HKD","BK4139","LU1868837300.USD","LU2242652126.USD","LU0323591593.USD","LU1914381329.SGD","R","PG","SG9999015341.SGD","SG9999002224.SGD","BK4567","BK4022","IE00B3T34201.USD","LU0868494617.USD","LU0061475181.USD","LU0234570918.USD","BK4218","SG9999014567.USD","LU0234572021.USD","LU0098860793.USD","BK4588","IE00B1XK9C88.USD","LU1868836757.USD","LU0096364046.USD","LU1162221912.USD","LU1430594728.SGD","IE00BWXC8680.SGD","PK","LU1868837136.USD","LU2129689431.USD","LU1585245621.USD","BK4559","LU1929549753.HKD","LU2552382132.HKD","IE000M9KFDE8.USD","EC","BK4201","BK4181","LU0237698245.USD","ARDS","LU0320765646.SGD","LU0640476718.USD","LU0124676726.USD","BK4018","IE00BLSP4452.SGD","LU0094547139.USD","IFRX","SG9999002232.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ecopetrol.com.co","stockEarnings":[{"period":"1week","weight":0.0291},{"period":"1month","weight":0.0739},{"period":"3month","weight":0.3396},{"period":"6month","weight":0.1802},{"period":"1year","weight":-0.1239},{"period":"ytd","weight":0.3396}],"compareEarnings":[{"period":"1week","weight":-0.0252},{"period":"1month","weight":-0.0559},{"period":"3month","weight":-0.0428},{"period":"6month","weight":-0.0121},{"period":"1year","weight":0.0743},{"period":"ytd","weight":-0.0428}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Ecopetrol S.A. operates as an integrated energy company. The company operates through four segments: Exploration and Production; Transport and Logistics; Refining, Petrochemical and Biofuels; and Electric Power Transmission and Toll Roads Concessions. It engages in the exploration and production of oil and gas; transportation of crude oil, motor fuels, fuel oil, and other refined products, including diesel, jet, and biofuels; processing and refining crude oil; distribution of natural gas and LPG; sale of refined and petrochemical products; supplying of electric power transmission services; design, development, construction, operation, and maintenance of road and energy infrastructure projects; and supplying of information technology and telecommunications services. As of December 31, 2022, the company had approximately 9,127 kilometers of crude oil and multi-purpose pipelines. It also produces and commercializes polypropylene resins and compounds, and masterbatches; and offers industrial service sales to customers and specialized management services. It has operations in Colombia, the United States, Asia, Central America and the Caribbean, Europe, and South America. The company was formerly known as Empresa Colombiana de Petróleos and changed its name to Ecopetrol S.A. in June 2003. Ecopetrol S.A. was incorporated in 1948 and is headquartered in Bogotá, Colombia.","yearOnYearQuotes":[{"month":1,"riseRate":0.588235,"avgChangeRate":0.035816},{"month":2,"riseRate":0.529412,"avgChangeRate":0.016842},{"month":3,"riseRate":0.705882,"avgChangeRate":0.021845},{"month":4,"riseRate":0.529412,"avgChangeRate":0.0045},{"month":5,"riseRate":0.3125,"avgChangeRate":-0.020769},{"month":6,"riseRate":0.4375,"avgChangeRate":0.003298},{"month":7,"riseRate":0.5,"avgChangeRate":0.011245},{"month":8,"riseRate":0.4375,"avgChangeRate":-0.006583},{"month":9,"riseRate":0.5,"avgChangeRate":-0.010678},{"month":10,"riseRate":0.588235,"avgChangeRate":-0.008192},{"month":11,"riseRate":0.411765,"avgChangeRate":-0.035339},{"month":12,"riseRate":0.588235,"avgChangeRate":0.009363}],"exchange":"NYSE","name":"Ecopetrol SA","nameEN":"Ecopetrol SA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.1","shortVersion":"4.32.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Ecopetrol SA(EC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Ecopetrol SA(EC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Ecopetrol SA,EC,Ecopetrol SA股票,Ecopetrol SA股票老虎,Ecopetrol SA股票老虎国际,Ecopetrol SA行情,Ecopetrol SA股票行情,Ecopetrol SA股价,Ecopetrol SA股市,Ecopetrol SA股票价格,Ecopetrol SA股票交易,Ecopetrol SA股票购买,Ecopetrol SA股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Ecopetrol SA(EC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Ecopetrol SA(EC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction